Consistent with the pioneering study in 1941, androgen deprivation therapy (ADT) constitutes the major therapeutic approach to prevent androgens from binding to the androgen receptor (AR) as the basis to treat PCa (Huggins & Hodges, 1972). The gene discussed is AR; the disease is posterior cortical atrophy.